✦ LIBER ✦

776 An economic analysis of the TAX 326 trial: a multicenter randomized study of docetaxel + cisplatin (DC) or docetaxel + carboplatin (DCb) vs. vinorelbine + cisplatin (VC) as first-line therapy in advanced non-small cell lung cancer (NSCLC)

✍ Scribed by N. Leighl; F.A. Shepherd; W.S. Tsao; P. Lindgren; C.B. Belani; F.V. Fossella; P.G. Goodwin

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multicenter, randomized phase III stud

✍ Belani, C.P; Rodriguez, J; von Pawel, J; Pluzanska, A; Gorbounova, V; Millward, 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 98 KB

P-452 Phase III study of docetaxel-cispl

✍ Belani, C.; von Pawel, J.; Pluzanska, A.; Gorbounova, V.; Kaukel, E.; Mattson, K 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Docetaxel + Cisplatin (DC) and Docetaxel

✍ F. Fossella 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 140 KB

O-51 Phase III study (TAX 326) of doceta

✍ Belani, Chandra P.; Fossella, Frank V. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 180 KB

P-463 Preliminary results of a multicent

✍ Bernardini, I.; Rinaldi, M.; Crinò, L.; Nardi, M.; De Marinis, F.; Tonato, M.; S 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 130 KB